HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.

Kwan AYM, Gerstein HC, Basile J, Xavier D, Maldonado JM, Raha S, Konig M

Diabetes care1 Mar 2022Cited by 6 (Europe PMC)

PMID35043140PMCIDPMC8918189DOI10.2337/dc21-1160PepBankPUB-35043140

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with diabetes, dulaglutide reduced HbA1c versus placebo throughout treatment, regardless of diabetes duration, microvascular disease, or BMI.
In plain wordsDulaglutide lowered HbA1c more than placebo regardless of diabetes duration, prior microvascular disease, or BMI.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c over treatment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 72 monthsAs given in this study (human).
Measurements
HbA1c least-squares mean difference
−0.61%
dulaglutide versus placebo
Source sentences
Summary
HbA1c was significantly reduced in patients treated with dulaglutide compared with placebo during 72 months of treatment (least-squares mean difference = -0.61%, P 0.07).
3 context sentences(design, population, supporting numbers)
Summary · context
Significant reductions were apparent at all time points and were independent of these baseline characteristics.
Summary · context
To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial.
Summary · context
Change from baseline in HbA1c was assessed during and up to 72 months of treatment before and after adjustment for duration of diabetes, prior microvascular disease (nephropathy or retinopathy), and BMI.
Report a problemFND-3504314001
02HumanNon-randomized trialEfficacy outcome
In patients with diabetes, dulaglutide produced faster HbA1c reduction than placebo before and after adjustment during initial treatment.
In plain wordsDulaglutide lowered HbA1c faster than placebo during initial treatment, before and after adjustment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c slope during initial treatment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 0-12 monthsAs given in this study (human).
Source sentences
Summary
Slope analyses revealed that the dulaglutide group experienced a higher rate of HbA1c reduction compared with the placebo group from 0 to 12 months before and after adjustment.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial.
Summary · context
Change from baseline in HbA1c was assessed during and up to 72 months of treatment before and after adjustment for duration of diabetes, prior microvascular disease (nephropathy or retinopathy), and BMI.
Report a problemFND-3504314002
03HumanNon-randomized trialEfficacy outcome
In patients with diabetes, HbA1c increased faster with dulaglutide than placebo before adjustment during later treatment.
In plain wordsDuring later treatment, HbA1c increased faster with dulaglutide than placebo before adjustment.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLater HbA1c slope before adjustment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 12-72 monthsAs given in this study (human).
Source sentences
Summary
The dulaglutide group also experienced a higher rate of HbA1c increase from 12 to 72 months compared with the placebo group that became nonsignificant after adjustment for diabetes duration, prior microvascular disease, and BMI combined.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial.
Summary · context
Change from baseline in HbA1c was assessed during and up to 72 months of treatment before and after adjustment for duration of diabetes, prior microvascular disease (nephropathy or retinopathy), and BMI.
Report a problemFND-3504314003
04HumanNon-randomized trialEfficacy outcome
In patients with diabetes, the later HbA1c slope difference versus placebo became nonsignificant after combined adjustment for baseline characteristics.
In plain wordsThe later HbA1c increase with dulaglutide did not differ significantly from placebo after adjustment.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeLater HbA1c slope after adjustment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 12-72 monthsAs given in this study (human).
Source sentences
Summary
The dulaglutide group also experienced a higher rate of HbA1c increase from 12 to 72 months compared with the placebo group that became nonsignificant after adjustment for diabetes duration, prior microvascular disease, and BMI combined.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial.
Summary · context
Change from baseline in HbA1c was assessed during and up to 72 months of treatment before and after adjustment for duration of diabetes, prior microvascular disease (nephropathy or retinopathy), and BMI.
Report a problemFND-3504314004
05HumanNon-randomized trialEfficacy outcome
During months 12-72, mean HbA1c with dulaglutide remained below baseline and below placebo values.
In plain wordsDuring later treatment, average HbA1c with dulaglutide remained below its starting level and below placebo values.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLater HbA1c versus baseline
Study
n: not reported in source
Comparator
Baseline and placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 12-72 monthsAs given in this study (human).
Source sentences
Summary
Despite the greater rate of HbA1c increase in the dulaglutide group during this period, mean HbA1c values remained below baseline in the dulaglutide group and below mean HbA1c values in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial.
Summary · context
Change from baseline in HbA1c was assessed during and up to 72 months of treatment before and after adjustment for duration of diabetes, prior microvascular disease (nephropathy or retinopathy), and BMI.
Report a problemFND-3504314005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01394952

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Eli Lilly and Companyn = 9,90122 Jul 2011 to 21 Aug 2018

Cardiovascular Disease · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.